Cargando…
Bioactive PI3-kinase/Akt/mTOR Inhibitors in Targeted Lung Cancer Therapy
One of the central signaling pathways with a regulatory effect on cell proliferation and survival is Akt/mTOR. In many human cancer types, for instance, lung cancer, the overexpression of Akt/mTOR has been reported. For this reason, either targeting cancer cells by synthetic or natural products affe...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tabriz University of Medical Sciences
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871280/ https://www.ncbi.nlm.nih.gov/pubmed/36721812 http://dx.doi.org/10.34172/apb.2023.003 |
_version_ | 1784877134428241920 |
---|---|
author | Ghareghomi, Somayyeh Atabaki, Vahideh Abdollahzadeh, Naseh Ahmadian, Shahin Hafez Ghoran, Salar |
author_facet | Ghareghomi, Somayyeh Atabaki, Vahideh Abdollahzadeh, Naseh Ahmadian, Shahin Hafez Ghoran, Salar |
author_sort | Ghareghomi, Somayyeh |
collection | PubMed |
description | One of the central signaling pathways with a regulatory effect on cell proliferation and survival is Akt/mTOR. In many human cancer types, for instance, lung cancer, the overexpression of Akt/mTOR has been reported. For this reason, either targeting cancer cells by synthetic or natural products affecting the Akt/mTOR pathway down-regulation is a useful strategy in cancer therapy. Direct inhibition of the signaling pathway or modulation of each related molecule could have significant feedback on the growth and proliferation of cancer cells. A variety of secondary metabolites has been identified to directly inhibit the AKT/mTOR signaling, which is important in the field of drug discovery. Naturally occurring nitrogenous and phenolic compounds can emerge as two pivotal classes of natural products possessing anticancer abilities. Herein, we have summarized the alkaloids and flavonoids for lung cancer treatment together with all the possible mechanisms of action relying on the Akt/mTOR pathway down-regulation. This review suggested that in search of new drugs, phytochemicals could be considered as promising scaffolds to be developed into efficient drugs for the treatment of cancer. In this review, the terms "Akt/mTOR", "Alkaloid", "flavonoid", and "lung cancer" were searched without any limitation in search criteria in Scopus, PubMed, Web of Science, and Google scholar engines. |
format | Online Article Text |
id | pubmed-9871280 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Tabriz University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-98712802023-01-30 Bioactive PI3-kinase/Akt/mTOR Inhibitors in Targeted Lung Cancer Therapy Ghareghomi, Somayyeh Atabaki, Vahideh Abdollahzadeh, Naseh Ahmadian, Shahin Hafez Ghoran, Salar Adv Pharm Bull Review Article One of the central signaling pathways with a regulatory effect on cell proliferation and survival is Akt/mTOR. In many human cancer types, for instance, lung cancer, the overexpression of Akt/mTOR has been reported. For this reason, either targeting cancer cells by synthetic or natural products affecting the Akt/mTOR pathway down-regulation is a useful strategy in cancer therapy. Direct inhibition of the signaling pathway or modulation of each related molecule could have significant feedback on the growth and proliferation of cancer cells. A variety of secondary metabolites has been identified to directly inhibit the AKT/mTOR signaling, which is important in the field of drug discovery. Naturally occurring nitrogenous and phenolic compounds can emerge as two pivotal classes of natural products possessing anticancer abilities. Herein, we have summarized the alkaloids and flavonoids for lung cancer treatment together with all the possible mechanisms of action relying on the Akt/mTOR pathway down-regulation. This review suggested that in search of new drugs, phytochemicals could be considered as promising scaffolds to be developed into efficient drugs for the treatment of cancer. In this review, the terms "Akt/mTOR", "Alkaloid", "flavonoid", and "lung cancer" were searched without any limitation in search criteria in Scopus, PubMed, Web of Science, and Google scholar engines. Tabriz University of Medical Sciences 2023-01 2021-10-09 /pmc/articles/PMC9871280/ /pubmed/36721812 http://dx.doi.org/10.34172/apb.2023.003 Text en ©2023 The Authors. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. |
spellingShingle | Review Article Ghareghomi, Somayyeh Atabaki, Vahideh Abdollahzadeh, Naseh Ahmadian, Shahin Hafez Ghoran, Salar Bioactive PI3-kinase/Akt/mTOR Inhibitors in Targeted Lung Cancer Therapy |
title | Bioactive PI3-kinase/Akt/mTOR Inhibitors in Targeted Lung Cancer Therapy |
title_full | Bioactive PI3-kinase/Akt/mTOR Inhibitors in Targeted Lung Cancer Therapy |
title_fullStr | Bioactive PI3-kinase/Akt/mTOR Inhibitors in Targeted Lung Cancer Therapy |
title_full_unstemmed | Bioactive PI3-kinase/Akt/mTOR Inhibitors in Targeted Lung Cancer Therapy |
title_short | Bioactive PI3-kinase/Akt/mTOR Inhibitors in Targeted Lung Cancer Therapy |
title_sort | bioactive pi3-kinase/akt/mtor inhibitors in targeted lung cancer therapy |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871280/ https://www.ncbi.nlm.nih.gov/pubmed/36721812 http://dx.doi.org/10.34172/apb.2023.003 |
work_keys_str_mv | AT ghareghomisomayyeh bioactivepi3kinaseaktmtorinhibitorsintargetedlungcancertherapy AT atabakivahideh bioactivepi3kinaseaktmtorinhibitorsintargetedlungcancertherapy AT abdollahzadehnaseh bioactivepi3kinaseaktmtorinhibitorsintargetedlungcancertherapy AT ahmadianshahin bioactivepi3kinaseaktmtorinhibitorsintargetedlungcancertherapy AT hafezghoransalar bioactivepi3kinaseaktmtorinhibitorsintargetedlungcancertherapy |